Navigation Links
Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
Date:3/13/2008

SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that it has initiated a Phase 2 study of RAV12, its lead clinical product, in combination with gemcitabine in the treatment of patients with metastatic pancreatic cancer.

The Phase 2 Pancreatic Cancer Study will be conducted at approximately 20 institutions in the US. The first institution to open the trial is the Fox Chase Cancer Center in Philadelphia, PA. Eight sites will participate through the clinical trials consortium, the Pancreatic Cancer Research Team. More information regarding the study can be found at http://www.clinicaltrials.gov.

After an initial dose-escalation run-in segment of approximately 18 patients, the Phase 2 trial will enroll 63 patients in an efficacy segment. The target dose and schedule of RAV12, 0.75 mg/kg twice weekly, was chosen in a recently completed Phase 1/2a trial that involved 53 patients. Final analysis of the Phase 1/2a study will be available the third quarter of 2008.

About RAV12

RAV12 is a novel, chimeric monoclonal antibody that is directed against a primate-specific glycotope (sugar structure) that is widely displayed on the surfaces of tumor cells, particularly those of gastrointestinal origin (gastroesophageal, pancreatic, and colorectal cancers). Preclinical studies have demonstrated that RAV12 may kill tumor cells in a number of ways: first, the antibody is directly cytotoxic to a human colon cancer cell line in vitro through induction of oncotic cell death, a form of cell death characterized by cell and organelle swelling and loss of membrane integrity; second, the antibody mediates antibody-dependent cellular cytotoxicity; third, the antibody mediates complement dependent cell killing; and finally, the antibod
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
2. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
3. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
4. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
5. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
6. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
7. Inclinix Announces New Patent for Expert System Platform
8. Genzyme Announces Presentation of New Positive Data on Carticel(R)
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is pleased ... of the first-of-its-kind comic book available in Canada ... been designed specifically to educate children and their parents about ... affecting more than 300,000 Canadians. Eisai is guided ... (hhc) , in which the patient is central – there ...
(Date:8/21/2014)... Aug. 21, 2014 /PRNewswire-iReach/ -- Inc. ... for the third straight year, No. 349 in ... exclusive ranking of the nation,s fastest-growing private companies. ... the most important segment of the economy—America,s independent ... Domino,s Pizza, LinkedIn, Zillow, and many other well-known ...
(Date:8/21/2014)... Aug. 21, 2014  Seventy-one percent of Americans believe the ... a serious public health and safety issue in ... survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication abuse problem ... this very serious health situation facing our country," Rex ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... thinking about cosmetic surgery, your first stop should be at ...   SculptMyDream.com is the first website to let individuals ... photography.  Not only will this help you "Sculpt YOUR dream", ... that dream into reality. (Photo:   http://photos.prnewswire.com/prnh/20110720/NY38494 ...
... 20, 2011 Landacorp , A Carewise Health ... solutions, today announced that its CareRadius Suite has been ... Coventry Health Care is a diversified national ... plans that serve more than five million members across ...
Cached Medicine Technology:See the Results of Your Breast Augmentation, Before Surgery 2Coventry Health Care Selects Landacorp's CareRadius Suite to Advance Collaborative Care 2
(Date:8/21/2014)... DoudouneCanadienneGoosePasCher.fr, one of the most popular suppliers ... its new selection of Trillium Parkas for 2014. Moreover, ... these fashionable and comfortable items are available at discounted ... last until September 01. , The CEO says ... Canada Goose Trillium Parkas for new and old ...
(Date:8/21/2014)... is an internationally well-known supplier and leader in the ... collection of elegant bamboo floorings . These new ... for high quality floorings for their own houses. Now, ... to 29 percent off). Before the end of August, ... The company’s bamboo flooring products are made using unique, ...
(Date:8/21/2014)... Mich. Using heart-lung support technology, the University of ... of kidneys, livers and pancreases available for transplant by ... the journal Transplantation and detail the impact ... Oxygenation, or ECMO, to improve the quality and viability ... "Organ transplant is limited by the number of donated ...
(Date:8/21/2014)... 2014 Improv performers from Fun House ... dementia at Silverado Turtle Creek memory care community in ... entertainers ranging from ages 10 to 16, delivers a ... 40-minute set. The troupe's philosophy is that improv is ... them to touch audiences regardless of their circumstance — ...
(Date:8/21/2014)... 21, 2014 (HealthDay News) -- Black mothers are less ... here,s one possible reason why: Hospitals in neighborhoods with ... those in areas with more white residents, a U.S. ... are much less common in medical centers where the ... U.S. Centers for Disease Control and Prevention reported Thursday. ...
Breaking Medicine News(10 mins):Health News:Fashionable And Comfortable Canada Goose Trillium Parkas For Sale At DoudouneCanadienneGoosePasCher.fr 2Health News:Buy Elegant Bamboo Floorings from Internationally Well-known Supplier BambooIndustry.com 2Health News:Extracorporeal support can significantly increase number of organs for transplant 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2
... , , HATBORO, Pa., Aug. 13 InfoLogix, Inc. ... solutions for the healthcare and commercial industries, today announced financial results for ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090618/NE3513 5 LOGO ... , , David T. Gulian, president and chief ...
... , , , BRISTOL, ... KG ) today announced that the U.S. Food and Drug ... Extended Release Capsules for oral use, a long-acting Schedule II ... when a continuous, around-the-clock opioid analgesic is needed for an ...
... , , REDWOOD ... ) today reported financial results and corporate progress for its fiscal ... , "With a slower than expected rate of ... quarter we had to make difficult decisions to revise our direct ...
... , , IRVINE, Calif., ... of surgical products used in the treatment of patients suffering from ... June 30, 2009. , , Net revenues in ... the prior year second quarter net revenues of $4,119,000. The ...
... rise if organ comes from deceased man, study finds, , ... donated organ came from a deceased male face an increased ... Canadian researchers have found. , The risk is short-term, though, ... researchers said. Their study found that the risk goes ...
... Genetic mutation could explain why some function fine on six hours ... few can get by just fine on six hours of sleep, ... why. , The finding doesn,t appear likely to help people with ... people sleep as long as they do, said study co-author Ying-Hui ...
Cached Medicine News:Health News:InfoLogix Announces Second Quarter Financial Results 2Health News:InfoLogix Announces Second Quarter Financial Results 3Health News:InfoLogix Announces Second Quarter Financial Results 4Health News:InfoLogix Announces Second Quarter Financial Results 5Health News:InfoLogix Announces Second Quarter Financial Results 6Health News:InfoLogix Announces Second Quarter Financial Results 7Health News:InfoLogix Announces Second Quarter Financial Results 8Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 2Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 3Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 4Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 5Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 6Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 7Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 2Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 3Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 4Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 5Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 6Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 7Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 8Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 9Health News:Cardiogenesis Reports Second Quarter 2009 Results 2Health News:Cardiogenesis Reports Second Quarter 2009 Results 3Health News:Cardiogenesis Reports Second Quarter 2009 Results 4Health News:Cardiogenesis Reports Second Quarter 2009 Results 5Health News:Cardiogenesis Reports Second Quarter 2009 Results 6Health News:Cardiogenesis Reports Second Quarter 2009 Results 7Health News:Kidney Donor's Sex Could Affect Women's Outcomes 2Health News:They Snooze Less, But They Don't Lose 2
High intensity halogen lamp with built-in, switchable spare. Optical light concentrator to optimize existing light energy....
... AlphaCor is a biocompatible, flexible, one-piece artificial ... or diseased native cornea., ,The World Health ... more than 10 million people worldwide, however ... year. This shortfall is due to a ...
PDA-version of the complete ICD-9 diagnosis codes....
PDA formatted guide containing outlines and detailed information on the diagnosis and treatment of HIV infection and AIDS....
Medicine Products: